Option chain shows key data for Ikena Oncology's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Ikena Oncology.

Ikena Oncology (NASDAQ:IKNA) Stock, Option Chain

Ikena Oncology

Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.

IKNA

Analyst Color

Biotech

News

Downgrades

Health Care

Price Target

Analyst Ratings

Movers

Trading Ideas

General

Ikena Oncology halts its IK-930 program after reviewing clinical data and resources, focusing on the novel MEK-RAF molecular glue, IK-595.

Ikena Oncology Discontinues IK-930 Program And Cuts Workforce, Analyst Calls It &#39;Disappointing&#39;

Intraday Update

Markets

ASTI

ASTS

AWIN

BNAI

BNZI

CAVA

CHWY

CNEY

CRKN

FFIE

GENE

GYRE

HLTH

IMVT

Kintara Therapeutics, Inc. - Common Stock

KTRA

LUCY

MBIO

MRVI

NEON

ONFO

OOMA

POAI

RSLS

SCPX

SMLR

SOBR

SOPH

SRDX

STSS

SYTA

TANH

TITN

TOST

VERU

Why Bank of Montreal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

Chicago,,Il,-,July,27,,2017:,American,Airlines,Plane,On

GSBD

This American Airlines Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

Ikena Oncology Inc

As Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) hit a new all-time high of $98,310 on Thursday morning during European trading hours, he total net asset value of U.S. Bitcoin spot exchange-traded funds (ETFs) has exceeded $100 billion, a milestone achieved in just 10 months since their <a href="https://www.benzinga.com/money/best-spot-bitcoin-etfs">launch in January</a>.
What Happened: Over the past three days, Bitcoin spot ETFs have seen $1.84 billion in net inflows, reflecting strong investor confidence. 
U.S.-based ETFs have contributed $29.4 billion in net flows this year, solidifying their role as a primary driver of capital into Bitcoin.
Nate Geraci, president of The ETF Store, <a href="https://x.com/NateGeraci/status/1859406924975845770">highlighted</a> on X the growing demand for spot ETFs and revealed that applications for funds linked to other digital assets, including Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>), Ripple (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>), and Hedera (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/hbar/usd">HBAR</a>), are also in the pipeline.
Bitcoin reached $97,900 earlier this week before climbing to $98,310, supported by aggressive demand for long-dated call options and positive headlines about corporate adoption, according to QCP Capital.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42099670/core-fusion-upgrade-introduces-dual-staking-and-liquid-bitcoin-staking">Core Fusion Upgrade Introduces Dual Staking And Liquid Bitcoin Staking</a>
Why It Matters: Companies like MicroStrategy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) are fueling the bullish sentiment, with the firm raising $2.6 billion to expand its Bitcoin holdings.
MicroStrategy's market capitalization has now surpassed $100 billion, dominating U.S. trading volume on Wednesday night.
In addition, smaller firms like Acurx Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACXP#NASDAQ">ACXP</a>) are joining the trend, reportedly allocating $1 million to Bitcoin for their corporate treasuries. 
The unprecedented success of Bitcoin ETFs signals a growing mainstream acceptance of cryptocurrencies. 
BlackRock (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NASDAQ">BLK</a>) and Fidelity are among the 12 issuers contributing to the $100 billion milestone, with analysts pointing to these funds as a significant factor in Bitcoin&#8217;s recent rally.
Eric Balchunas, a senior ETF analyst at Bloomberg, noted that December 31 could be an optimal time to submit applications for new crypto ETFs, including one linked to Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>). 
Meanwhile, aggressive buying of options for March and June indicates long-term bullish sentiment among investors.
As Bitcoin approaches the $100,000 psychological milestone, the market is expected to remain buoyant, supported by easing monetary policies and <a href="https://www.benzinga.com/news/events/24/11/42078359/blackrocks-head-of-digital-assets-says-ibit-spot-bitcoin-etf-options-blow-past-1-billion-in-trading-volume">sustained institutional demand.</a>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42096519/bitcoin-to-reach-190000-this-cycle-michael-terpin-of-transform-group-says">Bitcoin To Reach $190,000 This Cycle, Michael Terpin Of Transform Ventures Says</a></li>
</ul>
Image created using artificial intelligence with Midjourney.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$DOGE

$HBAR

$SOL

$XRP

ACXP

MSTR

Bitcoin Hits New All-Time High Above $98,000 As Spot ETFs Crack $100 Billion Net Asset Value Milestone

Northland Capital Markets analyst Mike Grondahl maintains Universal Technical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UTI#NYSE">UTI</a>) with a Outperform and raises the price target from $20 to $24.

Northland Capital Markets Maintains Outperform on Universal Technical, Raises Price Target to $24

Northland Capital Markets analyst Nehal Chokshi reiterates Palo Alto Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) with a Market Perform and raises the price target from $350 to $370.

Reiteration

PANW

Northland Capital Markets Reiterates Market Perform on Palo Alto Networks, Raises Price Target to $370

Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRCA#NASDAQ">VRCA</a>), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the pricing of an underwritten public offering of 44,964,045 shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase 2,235,955 shares of its common stock, and in either case, accompanying Series A warrants to purchase 23,600,000 shares of its common stock at an exercise price of $1.0680 per share of common stock and Series B warrants to purchase 23,600,000 shares of its common stock at an exercise price of $1.3350 per share of common stock, at a combined public offering price of $0.89 per share of common stock and accompanying Series A and Series B warrants (or $0.8899 per pre-funded warrant and accompanying Series A and Series B warrants). All of the securities being sold in the offering are being sold by Verrica. The offering is expected to close on November 22, 2024, subject to the satisfaction of customary closing conditions. Verrica also granted the underwriter an option for a period of 30 days to purchase up to 7,080,000 additional shares of the Company's common stock and/or Series A warrants to purchase up to 3,540,000 additional shares of its common stock and Series B warrants to purchase up to 3,540,000 additional shares of its common stock at the public offering price, less the underwriting discounts and commissions.

Financing

Offerings

VRCA

Verrica Pharmaceuticals Priced Its Underwritten Public Offering Of $42M At A Combined Public Offering Price Of $0.89/Share And Accompanying Series A And Series B Warrants

D. Boral Capital analyst Jason Kolbert maintains Invivyd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVVD#NASDAQ">IVVD</a>) with a Buy and maintains $9 price target.

IVVD

D. Boral Capital Maintains Buy on Invivyd, Maintains $9 Price Target

JMP Securities analyst Trevor Walsh maintains Palo Alto Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) with a Market Outperform and raises the price target from $380 to $415.

JMP Securities Maintains Market Outperform on Palo Alto Networks, Raises Price Target to $415

AMAT

Applied Materials Introduces MAX OLED Solution, A Patented OLED Pixel Architecture And Revolutionary Display Manufacturing Technology

Vestis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSTS#NYSE">VSTS</a>) sees FY2025 sales of $2.800 billion-2.830 billion vs $2.85 billion estimate.

Guidance

VSTS

Vestis Sees FY2025 Sales $2.800B-$2.830B vs $2.85B Est

Government

Contracts

ZENA

ZenaTech Has Signed Blue Unmanned Aerial Systems And US National Defense Authorization Act Compliant Partner Agreements For Its Supply Chain To Sell Its ZenaDrone 1000 AI Drone Solutions To US Defense Branches And To NATO Forces

Fiscal 2025 Outlook
As previously announced, CPI's outlook for fiscal 2025 with regard to revenue, net income, Adjusted EBITDA and Adjusted EBITDA Margin is as follows:
<ul>
<li>Revenue in the range of $2.48 billion to $2.58 billion</li>
<li>Net income in the range of $97 million to $113 million</li>
<li>Adjusted EBITDA(1) in the range of $347 million to $377 million</li>
<li>Adjusted EBITDA Margin(1) in the range of 14.0% to 14.6%</li>
</ul>

ROAD

Construction Partners Now Expects FY25 Revenue Of $2.48B-$2.58B (From $2.42B - $2.52B) Vs. Est $2.48B

He will continue to serve as CFO until December 31, 2024 to ensure a smooth transition.
Shyft's Board of Directors is commencing a comprehensive search for a new CFO, supported by a leading, independent executive search firm. The Company is considering both internal and external succession candidates.

Management

SHYF

Shyft Group Says Jon Douyard Has Resigned As CFO To Pursue Another Professional Opportunity Outside The Industry

WIIM

Conduit Pharmaceuticals shares are trading higher after the company announced that the Japan Patent Office granted a composition of matter patent for its lead asset, AZD1656.

This approval follows the recent patent grant in Australia, highlighting Conduit's continued progress in safeguarding its intellectual property portfolio for future out-licensing opportunities.

Conduit Pharmaceuticals Says Japan Patent Office Granted Approval Of A Composition Of Matter Patent Application For Lead Asset AZD1656

Telsey Advisory Group analyst Joseph Feldman maintains Target (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) with a Outperform and lowers the price target from $195 to $150.

Telsey Advisory Group Maintains Outperform on Target, Lowers Price Target to $150

GXAI

Gaxos.ai Announced That The Company Has Integrated Suno AI And Elevenlabs Into Their Artificial Intelligence Solution For Game Developers And Publishers, Gaxos Labs

IDXX

IDEXX Names Andrew Emerson To Serve As Next CFO, Effective March 1, 2025; Brian McKeon To Retire In June 2025

Telsey Advisory Group analyst Cristina Fernandez maintains Williams-Sonoma (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) with a Outperform and raises the price target from $165 to $190.

Telsey Advisory Group Maintains Outperform on Williams-Sonoma, Raises Price Target to $190

Evogene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGN#NASDAQ">EVGN</a>) reported quarterly losses of $(1.31) per share which missed the analyst consensus estimate of $(0.63) by 107.94 percent. The company reported quarterly sales of $1.80 million which missed the analyst consensus estimate of $2.85 million by 36.98 percent. This is a 52.32 percent decrease over sales of $3.77 million the same period last year.

Earnings

EVGN

Evogene Q3 2024 GAAP EPS $(1.31) Misses $(0.63) Estimate, Sales $1.80M Miss $2.85M Estimate

Construction Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROAD#NASDAQ">ROAD</a>) reported quarterly earnings of $0.56 per share which missed the analyst consensus estimate of $0.57 by 1.75 percent. The company reported quarterly sales of $538.163 million which beat the analyst consensus estimate of $538.050 million by 0.02 percent. This is a 13.29 percent increase over sales of $475.026 million the same period last year.

Earnings Beats

Earnings Misses

Construction Partners Q4 2024 GAAP EPS $0.56 Misses $0.57 Estimate, Sales $538.163M Beat $538.050M Estimate

Buybacks

Kyndryl Board Authorizes $300M Share Repurchase Program

GWAY, RSLS and GV are among mid-day movers

Ikena Oncology (IKNA) just unveiled an update. Ikena Oncology, Inc. has elevated Jotin Marango, M.D., Ph.D. to the role of Chief Operating Officer ...

Ikena Oncology Promotes Jotin Marango to Chief Operating Officer

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Ikena Oncology (NASDAQ:<a href="https://investorplace.com/stock-quotes/ikna-stock-quote/">IKNA</a>) just reported results for the second quarter of 2024.<ul><li>Ikena Oncology reported earnings per share of -28 cents. This was above the analyst estimate for EPS of -35 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/ikna-stock-earnings-ikena-oncology-for-q2-of-2024/">IKNA Stock Earnings: Ikena Oncology Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

IKNA Stock Earnings: Ikena Oncology Beats EPS for Q2 2024

Ikena Oncology GAAP EPS of -$0.28

In a report released today, David Nierengarten from Wedbush maintained a Hold rating on Ikena Oncology (IKNA – Research Report), with a price targe...

Wedbush Sticks to Its Hold Rating for Ikena Oncology (IKNA)

H.C. Wainwright analyst Andres Y. Maldonado has reiterated their bullish stance on IKNA stock, giving a Buy rating on August 9. Andres Y. Maldonado...

Ikena Oncology's IK-595 Shows Promising Potential as a Best-in-Class Dual RAF/MEK Inhibitor: Analyst Maintains Buy Rating

Ikena Oncology, Inc. (IKNA) has disclosed a new risk, in the Employment / Personnel category. Ikena Oncology, Inc. faces a significant business ris...

Ikena Oncology's Gamble: Slashing Workforce by Half Could Derail Strategic Plans

As of September 30, 2024, the Company had cash, cash equivalents, and marketable securities of $138.0 million. Published first on TheFly – the ulti...

iKena Oncology reports Q3 EPS (21c), consensus (27c)

Ikena Oncology GAAP EPS of -$0.21 beats by $0.06

Ikena Oncology, Inc. ( ($IKNA) ) has released its Q3 earnings. Here is a breakdown of the information Ikena Oncology, Inc. presented to its investo...

Ikena Oncology Reports Strategic Realignment and Financial Performance

AMPG

GWAV

PLTN

RNAZ

SERV

VNCE

Press Releases

Ikena Oncology Outlines Key Priorities and Provides Corporate Updates

Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer

Ikena Oncology to Participate in TD Cowen 44th Annual Health Care Conference

Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial Results

Ikena Oncology to Present at the Stifel 2024 Virtual Targeted Oncology Forum

Ikena Oncology Reports First Quarter 2024 Financial Results and Corporate Update

Comments

Ikena Oncology

Ikena Oncology (IKNA) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga